V8 Peptides — Engineered Performance
Research Library
AOD-9604 Preclinical Literature: Study by Study
AOD-9604Preclinical

AOD-9604 Preclinical Literature: Study by Study

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What does the preclinical literature on AOD-9604 contain? A small set of studies: oral and infused fragment work in ob/ob mice and Zucker rats (2000–2001), receptor-binding and beta-3 receptor experiments, a 2015 rabbit joint study, and analytical papers on detection and metabolism. Abstracts report direction and significance more than effect sizes, and independent replication is not evident. Supplied for laboratory research use only.

The published preclinical literature on AOD-9604 is small enough to read in an afternoon and uneven enough to need a guide. A handful of rodent and in vitro studies from the early 2000s established the main claims, one rabbit joint study appeared in 2015, and a few analytical papers since then describe how the peptide is detected and metabolized. This article reviews that literature study by study, says what each paper reports according to its abstract, flags what it cannot support, and lists the gaps. It is a literature review for laboratory researchers, not an assessment of any use outside a laboratory, and it draws only on what the abstracts state.

Compound facts come from the AOD-9604 product page: AOD-9604, hGH fragment 176-191, a 16-residue peptide with the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe and one intramolecular disulfide bond, supplied as a lyophilized powder in a 5 mg vial for laboratory research use only. Mechanism-focused discussion is in the library's AOD-9604 research overview and AOD-9604 vs the hGH 176-191 fragment; this article is organized by paper.

Background: why a growth hormone fragment

Growth hormone has several metabolic actions, and lipolysis is prominent. A review of its effects in human subjects describes the most prominent metabolic effect of GH as a marked increase in lipolysis and free fatty acid levels, and notes that GH is a counterregulatory hormone that antagonizes the effects of insulin on glucose metabolism (Møller and Jørgensen, 2009). The rationale for a fragment follows: if a short C-terminal sequence retains lipolytic activity while avoiding actions mediated through the intact hormone's receptor, it would be useful for separating those effects experimentally. Whether AOD-9604 achieves that separation is what the early papers tested, and it is why they paired the fragment with intact hGH in the same experiments.

Study 1: oral C-terminal fragment AOD-9401 in ob/ob mice and human adipose tissue

A 2000 paper in the American Journal of Physiology reported the effects of oral administration of a synthetic hGH fragment, designated AOD-9401, in rodent obesity models and in human adipose tissue (Heffernan et al., 2000). Note the designation: the abstract names AOD-9401, a related fragment, not AOD-9604, and the paper is therefore cited here as precursor work. In C57BL/6J ob/ob mice exposed orally with saline (n=8) or AOD-9401 (n=10) for 30 days, body weight gain was significantly lower in exposed animals from day 16 onward, while food consumption did not differ between groups. Ex vivo, adipose tissue from exposed animals showed reduced lipogenic activity and increased lipolytic activity, and the paper reported an acute increase in energy expenditure and in glucose and fat oxidation. The fragment also increased lipolytic activity and decreased lipogenic activity in isolated adipose tissue from obese rodents and humans in vitro. What the abstract does not report is anything about AOD-9604 itself; the value of the paper is as a statement of the hypothesis.

Study 2: AOD9604 in obese Zucker rats

A 2000 paper in Hormone Research examined AOD9604 in obese Zucker rats. Daily oral exposure with 500 µg/kg body weight for 19 days reduced body weight gain by more than 50% relative to control (15.8 ± 0.6 g versus 35.6 ± 0.8 g), adipose tissue from exposed animals showed increased lipolytic activity, and, in contrast to chronic exposure with intact hGH, chronic AOD9604 showed no adverse effect on insulin sensitivity as measured by euglycemic clamp (Ng et al., 2000). The authors concluded that the analogue may have potential for further development as an orally active compound; that is their forward-looking statement and not a claim made here. Two features limit generalization: one species and strain, and a single dose.

Study 3: chronic exposure in obese and lean mice, with receptor-binding controls

A 2001 International Journal of Obesity paper exposed obese (ob/ob) and lean C57BL/6J mice with hGH, AOD9604 or saline for 14 days using mini-osmotic pumps and measured body weight, caloric intake, resting energy expenditure, fat oxidation, glucose oxidation and plasma markers (Heffernan et al., 2001a). Both hGH and AOD significantly reduced body weight gain in obese mice, associated with increased in vivo fat oxidation and increased plasma glycerol, an index of lipolysis. Unlike hGH, AOD9604 did not induce hyperglycaemia or reduce insulin secretion. In vitro experiments in BaF-BO3 cells transfected with the hGH receptor showed that AOD9604 does not compete for the hGH receptor and does not induce cell proliferation, unlike hGH. This paper is the most direct support in the literature for the claim that the fragment acts through a route distinct from the hormone's receptor, and it provides the receptor-binding control that the first two studies lacked.

Study 4: the beta-3 adrenergic receptor experiments

A second 2001 paper, in Endocrinology, examined the role of the beta-3 adrenergic receptor (Heffernan et al., 2001b). Both hGH and AOD9604 reduced body weight and body fat in obese mice after 14 days of chronic intraperitoneal administration, and the effects correlated with increased expression of beta-3 receptor RNA, which both compounds raised in obese mice to levels comparable with lean mice. In beta-3 receptor knockout mice, long-term exposure failed to produce the change in body weight and increase in lipolysis seen in wild-type controls, which showed the importance of the receptor. However, in an acute experiment, AOD9604 still increased energy expenditure and fat oxidation in the knockout mice. The authors concluded that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the beta-3 receptor, although both increase its expression, which may subsequently contribute to enhanced lipolytic sensitivity. The nuance is important: the paper does not say AOD9604 binds or activates the beta-3 receptor; it says the long-term effects depend on the receptor being present and that expression rises.

StudyModelRoute and durationPrincipal reported findingsKey limitation
Heffernan et al., 2000 (AOD-9401)ob/ob mice; human and rodent adipose tissueOral, 30 daysLower weight gain; more lipolysis, less lipogenesis ex vivoDifferent fragment designation
Ng et al., 2000Obese Zucker ratsOral, 19 days, 500 µg/kgAbout 56% less weight gain than control; no adverse effect on insulin sensitivity by clampOne dose; one strain
Heffernan et al., 2001aob/ob and lean mice; hGH-receptor cell lineMini-osmotic pump, 14 daysReduced weight gain; more fat oxidation; no hGH-receptor competitionAbstract gives no per-group effect sizes
Heffernan et al., 2001bObese mice; beta-3 receptor knockoutsIntraperitoneal, 14 daysBeta-3 receptor expression rose; knockouts lacked the chronic effectMechanism is indirect
Kwon and Park, 2015Collagenase-induced knee osteoarthritis in rabbits (n=32)Weekly intra-articular, 4–7 weeksLower cartilage-degeneration scores with AOD9604; lower still combined with hyaluronic acidSmall groups; one model

Study 5: the rabbit joint model

The 2015 paper in Annals of Clinical and Laboratory Science moved the fragment outside metabolism. Using mature New Zealand white rabbits (n=32) given collagenase twice in each knee, the authors compared weekly intra-articular administrations of saline, hyaluronic acid, 0.25 mg AOD9604, and AOD9604 with hyaluronic acid (Kwon and Park, 2015). Gross morphological and histopathological scores were significantly higher in the saline group than in the other three groups and significantly lower in the combination group than in the hyaluronic acid and AOD9604 groups; lameness was shorter in the combination group than in the other groups. The authors concluded that AOD9604 enhanced cartilage regeneration and that the combination was more effective than either alone in this collagenase-induced model. For a laboratory reader the significance is the breadth of the claim, a joint outcome from a metabolic fragment, together with its narrowness of evidence: one model, a small number of animals, an injury-induced rather than spontaneous disease, and a single research group. This article reports the result and does not extend it.

Analytical papers: detection and metabolism

Two analytical papers complete the picture. A 2014 paper in Drug Testing and Analysis reported a solid-phase extraction method validated in urine with a limit of detection of 50 pg/mL, identified six potential metabolites after incubation of AOD9604 in serum and urine, and found one metabolite, consisting of amino acids CRSVEGSCG, that was significantly more stable than the parent compound (Cox et al., 2014). The abstract notes that the peptide is available on several internet websites and was identified in confiscated vials in the USA, and describes AOD9604 as banned by the World Anti-Doping Agency. A 2013 paper reported that AOD-9604 does not influence the WADA hGH isoform immunoassay (Orlovius et al., 2013); its abstract text was not available to the author, so it is cited only for its title. For the sport-regulatory status, see research peptide legal status in the US.

The metabolite finding has a bench-level consequence: the fragment CRSVEGSCG lies inside the disulfide loop, from the first cysteine to the second, which is why a quality or stability study of AOD-9604 should look at fragments as well as the parent mass. The product-page statement that the molecule has one intramolecular disulfide bond is the structural fact behind that point; see AOD-9604 purity testing for the analytical side.

What the literature has not shown

  • Independent replication. The metabolic claims rest on the 2000–2001 papers; repeat studies by other groups are not evident in the sources read for this article.
  • Dose-response and time-course in several models. Ng et al. used one dose; the others do not report a range in their abstracts.
  • Effect sizes in the mouse studies. The abstracts report direction and significance, not magnitudes, so quantitative comparison across studies is impossible from the abstracts alone.
  • Direct receptor identification. What AOD9604 binds is not established in the abstracts; they report what it does not bind (the hGH receptor) and what is required for chronic effects (the beta-3 receptor).
  • Human outcome data in the peer-reviewed sources read. This article does not summarize any, and it does not suggest any.

Where the studies sit in time

The table orders the sources by year, to show how thin and how old the metabolic evidence base is relative to the amount of text written about the peptide.

YearTypeSource
2000Rodent metabolic (related fragment AOD-9401)Heffernan et al.
2000Rodent metabolic (AOD9604)Ng et al.
2001Mouse metabolic and receptor-binding controlsHeffernan et al.
2001Mouse and beta-3 knockoutHeffernan et al.
2013Doping-control immunoassayOrlovius et al.
2014–2015Detection and metabolismCox et al.
2015Rabbit joint modelKwon and Park

Using this literature in a bench plan

For a laboratory, the useful lessons are about controls. Compare the fragment with intact hGH in the same experiment, as the early papers did. Include a receptor-binding or receptor-dependence control, as the 2001 papers did with the hGH receptor cell line and the knockout mice. Report effect sizes and dose ranges, which the abstracts do not. Document the material: identity, purity and counterion, since a disulfide-containing peptide can differ between lots in ways a purity percentage does not show; see AOD-9604 purity testing. The product page marks its certificate status as in progress, so a lab should record identity and purity as unverified until a certificate for its lot is published on the COA page or the lab tests the material itself. Stock arithmetic is mass divided by volume (1 mL into the 5 mg vial gives 5 mg/mL); the calculator handles other volumes. The catalogue is on the shop page; AOD-9604 is supplied strictly for laboratory research use only.

Frequently asked questions

How many primary preclinical papers on AOD-9604 are there?

This review found four early metabolic studies from 2000–2001 (one of them on a related fragment, AOD-9401), one 2015 rabbit joint study and two analytical papers. The list is not claimed to be exhaustive.

Which animals were used?

Obese ob/ob and lean mice, obese Zucker rats, beta-3 receptor knockout mice, and New Zealand white rabbits, depending on the study.

Does AOD9604 bind the growth hormone receptor?

According to the 2001 International Journal of Obesity abstract, it does not compete for the hGH receptor and does not induce proliferation in cells expressing it, unlike hGH.

Does AOD9604 act through the beta-3 adrenergic receptor?

The Endocrinology abstract reports that chronic effects were absent in beta-3 knockout mice and that expression rose with exposure, but concludes the lipolytic actions are not mediated directly through that receptor.

What did the Zucker rat study report?

Daily oral AOD9604 at 500 µg/kg for 19 days reduced weight gain by more than 50% versus control and, unlike chronic hGH, showed no adverse effect on insulin sensitivity in euglycemic clamp experiments.

Why does the rabbit study matter?

It is the only paper read that reports a joint outcome. It used 32 rabbits and a collagenase model, so it is a narrow evidence base.

What is the stable metabolite described in the analytical paper?

A fragment consisting of amino acids CRSVEGSCG, reported as significantly more stable than the parent compound and other metabolites in serum.

Are effect sizes available?

Not in most of the abstracts read. They report direction and significance, so quantitative comparison needs the full papers.

Is there a published certificate for V8 AOD-9604?

The product page currently marks it as in progress. Regard identity and purity as unverified for a lot until a certificate is published or you test the material.

Is AOD-9604 sold for use outside the laboratory?

No. It is supplied strictly for laboratory research use only and is not intended for human or animal consumption.

Related reading: AOD-9604 Reconstitution Math and Rodent Study Parameters, AOD-9604 in Rodent Models: Obese Mice and Zucker Rats, AOD-9604 Purity: Disulfide Quality and COA Checks.

References

  1. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152-177. doi:10.1210/er.2008-0027
  2. Heffernan M, et al. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. doi:10.1152/ajpendo.2000.279.3.E501
  3. Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053183
  4. Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740
  5. Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
  6. Kwon DR, Park GY. Effect of intra-articular AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426-432. PMID: 26275694
  7. Cox HD, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-38. doi:10.1002/dta.1715
  8. Orlovius AK, et al. AOD-9604 does not influence the WADA hGH isoform immunoassay. Drug Test Anal. 2013;5(11-12):850-852. doi:10.1002/dta.1557

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.